IP Library › Granted Patent US 12,502,559
Granted Patent B2
US 12,502,559 · App. 18/768,110 · Granted Dec 23, 2025

Bronchial denervation using integrated A-mode signal for optimization of ultrasound treatment

Inventors: Reinhard J. Warnking (Westlake, FL); Satoshi Nishiaoki (Setauket, NY)
Assignee: AerWave Medical, Inc.
A61N7/00A61B8/085A61B8/12A61B8/429A61N7/022A61B1/00082A61N2007/0004A61N2007/003A61N2007/0043A61N2007/0052A61N2007/0082
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,502,559
App. No.
18/768,110
Granted
Dec 23, 2025
Kind
B2
Abstract

Apparatus and methods for deactivating bronchial nerves extending along a bronchial branch of a mammalian subject to treat asthma and related conditions. An ultrasonic transducer ( 11 ) is inserted into the bronchus as, for example, by advancing the distal end of a catheter ( 10 ) bearing the transducer into the bronchial section to be treated. The ultrasonic transducer emits focused ultrasound so as to heat tissues throughout circular impact volume ( 13 ) as, for example, at least about 1 cm 3 encompassing the bronchus to a temperature sufficient to inactivate nerve conduction but insufficient to cause rapid ablation or necrosis of the tissues. The treatment can be performed without locating or focusing on individual bronchial nerves.

Claims (33)

1 . A method for treating adverse respiratory symptoms in a mammalian subject, comprising:

inserting an ultrasound transducer into a bronchial tree of the mammalian subject; and

operating, a processor electrically connected to the ultrasound transducer, to energize the ultrasound transducer to emit a short pulse at a sub-therapeutic level;

receiving via the ultrasound transducer circumferential A-mode ultrasound echoes from organic tissues of the mammalian subject in response to the short pulse;

operating the processor to process the circumferential A-mode ultrasound echoes into a volume integrated signal, which represents an accumulated intensity of the circumferential A-mode ultrasound echoes;

analyzing the volume integrated signal to determine locations of bronchial cartilage rings; and

activating the ultrasound transducer to transmit ultrasound therapeutic waveform energy between adjacent bronchial cartilage rings.

2 . The method of claim 1 , further comprising moving the ultrasound transducer to a position adjacent a space or gap between the adjacent bronchial cartilage rings prior to the activating of the ultrasound transducer to transmit the ultrasound therapeutic waveform energy.

3 . The method of claim 1 wherein the ultrasound transducer includes multiple separately activatable transducer elements, the activating of the ultrasound transducer includes energizing the separately activatable transducer elements to direct the ultrasound therapeutic waveform energy between the adjacent bronchial cartilage rings.

4 . The method of claim 1 , further comprising analyzing the volume integrated A-mode signal to detect presence of air pockets or trapped air between a balloon and bronchus, wherein only if the volume integrated A-mode signal reveals an absence of air is the ultrasound transducer activated to transmit ultrasound therapeutic waveform energy, thereby ensuring complete circumferential coupling.

5 . The method of claim 1 , further comprising operating the processor to process an electrical signal to measure time delay of the ultrasound echo waveform relative to a time of emission of the short pulse to determine diameter of a bronchial section to be treated, wherein the activating of the ultrasound transducer to transmit ultrasound therapeutic waveform energy includes activating the ultrasound transducer at an acoustic power level in accordance with a determined size of the bronchial section.

6 . The method of claim 1 , wherein the activating of the ultrasound transducer includes transmitting an amount of ultrasound therapeutic waveform energy into an impact volume circumferentially surrounding a bronchial section, in an amount therapeutically effective to inactivate conduction of all bronchial nerves in the impact volume.

7 . The method of claim 1 , wherein for an impact volume of approximately 1 cm3, the ultrasound therapeutic waveform energy is transmitted at an acoustic power level of approximately 10 to approximately 50 watts for approximately 10 to approximately 20 seconds to provide an absorbed dose of approximately 100 to approximately 1000 joules throughout the impact volume.

8 . The method of claim 1 , wherein the ultrasound therapeutic waveform energy is transmitted so as to maintain the temperature of a bronchial wall section surrounding the ultrasound transducer below 65° C. while heating bronchial nerves in a circumferential impact volume about the bronchial wall section to above 42° C.

9 . The method of claim 1 , wherein the inserting of the ultrasound transducer into the bronchial tree is performed through a working channel of a bronchoscope under visual guidance, or through a steerable sheath, or with a steerable ultrasound catheter through an oral intubating device, or under optical imaging guidance with an optical fiber inserted through the central lumen of the steerable ultrasound treatment catheter, or without a sheath or bronchoscope, directly through an oral intubation device with a steerable ultrasound catheter with a distance scale marking for monitoring degree of insertion after conducting a computed tomography or magnetic resonance imaging procedure to ascertain distance along the bronchial tree to a bronchial section.

10 . The method of claim 1 , further comprising:

inserting an air filled balloon into the esophagus of the patient;

monitoring the volume integrated A-mode signal;

advancing the treatment catheter distally beyond the first bifurcation until an esophageal signal caused by the air filled balloon inside the esophagus is diminished, thereby enabling prevention of peri esophageal nerve damage; and

circulating a cooling fluid through the balloon, displacing the air, and thereby reducing peri-esophageal nerve damage.

11 . The method of claim 1 , wherein the ultrasound transducer is mounted to a distal end of a catheter, the inserting of the ultrasound transducer into the bronchial tree includes inserting the catheter so that the ultrasound transducer is placed at an operating position determined at least in part based on a bending radius of a distal catheter portion monitored via strain gauges.

12 . The method of claim 1 , wherein monitoring diameters of trachea and bifurcated bronchi is utilized to determine transducer position.

13 . Apparatus for inactivating bronchial nerve conduction in a mammalian subject, comprising:

an ultrasound transducer adapted for insertion into a bronchial tree of the mammalian subject and for emitting ultrasound energy; and

a processor electrically connected to the ultrasound transducer, the processor being configured to activate the ultrasound transducer to emit a short pulse at a sub-therapeutic level;

the ultrasound transducer being connected to the processor for receiving circumferential A-mode ultrasound echoes from organic tissues of the mammalian subject in response to the short pulse;

the processor being further configured to process the circumferential A-mode ultrasound echoes into a volume-integrated signal which represents an accumulated intensity of the circumferential A-mode ultrasound echoes;

wherein the processor is further configured to analyze the volume integrated signal to distinguish a relative minimum of the volume-integrated A-mode signal with respect to a degree of insertion of the ultrasound transducer in the bronchial tree, thereby enabling positioning of the ultrasound transducer to transmit therapeutically effective focused ultrasound energy into a treatment or impact volume between bronchial cartilage rings.

14 . The apparatus of claim 13 wherein the processor is configured to measure time delay of the A-mode ultrasound echoes and therewith determine size of a bronchial section, the processor further configured to control the ultrasound transducer to vary the amount of the therapeutically effective focused ultrasound energy in accordance with the determined size of a bronchial section.

15 . The apparatus of claim 13 wherein the ultrasound transducer includes a longitudinal array of separately activatable transducer elements and the processor is configured to energize the separately activatable transducer elements in a sequence to direct the ultrasound therapeutic waveform energy between adjacent bronchial cartilage rings.

16 . The apparatus of claim 13 wherein the processor is configured to analyze the A-mode ultrasound echoes to facilitate complete circumferential coupling.

17 . The apparatus of claim 13 wherein the ultrasound transducer is provided on a steerable ultrasound catheter with a distance scale marking for monitoring degree of insertion after conducting a computed tomography or magnetic resonance procedure to ascertain distance along the bronchial tree to a bronchial section.

18 . The apparatus of claim 13 wherein the ultrasound transducer is provided on a catheter with strain gauges.

Assignments (1)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 10, 2024
From: WARNKING, REINHARD J.; NISHIAOKI, SATOSHI
To: AERWAVE MEDICAL, INC.
Reel/Frame 067944/0644 →
Continuity (4)
Continuation 18389933 · Dec 20, 2023
Continuation 17418545
Provisional Application 63002555 · Mar 31, 2020
Related Publication 20240366967A1 · Nov 7, 2024
References Cited (55)
US 6984993B2 · Ariav · 2006 [cited by applicant]
US 8425455B2 · Nentwick · 2013 [cited by applicant]
US 8992447B2 · Gertner · 2015 [cited by applicant]
US 10828462B2 · Daniels et al. · 2020 [cited by applicant]
US 11020618B1 · Warnking · 2021 [cited by applicant]
US 11273330B2 · Warnking · 2022 [cited by applicant]
US 11278313B2 · Warnking · 2022 [cited by applicant]
US 11446524B2 · Mayse et al. · 2022 [cited by applicant]
US 11565135B2 · Warnking · 2023 [cited by examiner]
US 11607568B2 · Warnking · 2023 [cited by examiner]
US 20030060813A1 · Loeb · 2003 [cited by applicant]
US 20030078645A1 · Pigott · 2003 [cited by applicant]
US 20030191392A1 · Haldeman · 2003 [cited by applicant]
US 20050222558A1 · Baxter · 2005 [cited by applicant]
US 20080287837A1 · Makin · 2008 [cited by applicant]
US 20110144491A1 · Sliwa · 2011 [cited by applicant]
US 20110245665A1 · Nentwick · 2011 [cited by applicant]
US 20110257523A1 · Hastings et al. · 2011 [cited by applicant]
US 20110257561A1 · Gertner · 2011 [cited by applicant]
US 20120143099A1 · Daniels et al. · 2012 [cited by applicant]
US 20130103028A1 · Tsoref · 2013 [cited by applicant]
US 20130197555A1 · Schaer et al. · 2013 [cited by applicant]
US 20130281889A1 · Gertner · 2013 [cited by applicant]
US 20140031727A1 · Warnking · 2014 [cited by applicant]
US 20160008636A1 · Warnking · 2016 [cited by applicant]
US 20160113699A1 · Sverdlik · 2016 [cited by applicant]
US 20160220851A1 · Mayse · 2016 [cited by applicant]
US 20160287912A1 · Warnking · 2016 [cited by examiner]
US 20170014159A1 · Stokes · 2017 [cited by applicant]
US 20180146839A1 · Friedlander et al. · 2018 [cited by applicant]
US 20200238085A1 · Khodaparast · 2020 [cited by applicant]
US 20200246069A1 · Rioux et al. · 2020 [cited by applicant]
US 20210316161A1 · Warnking et al. · 2021 [cited by applicant]
US 20220008753A1 · Warnking et al. · 2022 [cited by applicant]
EP 1159036 · 2007 [cited by applicant]
EP 2521593 · 2015 [cited by applicant]
WO WO2007009118 · 2007 [cited by applicant]
WO WO2011053757 · 2011 [cited by applicant]
WO WO2012120495 · 2012 [cited by applicant]
WO WO2013048912 · 2013 [cited by applicant]
WO WO2014022777 · 2014 [cited by applicant]
WO WO2015066424 · 2015 [cited by applicant]
WO WO2021201963 · 2021 [cited by applicant]
Armitage, L., & Rachel, B. (2020, Jun. 22). Inhaled corticosteroids: A rapid review of the evidence for treatment or prevention of COVID-19. Retrieved Aug. 20, 2020, from https://www.cebm.net/covid-19/inhaled-corticoste… [cited by applicant]
Buehler, Markus J. “Nanomechanical sonification of the 2019-nCOV coronavirus spike protein through a materiomusical approach.” Apr. 2, 2020, https://web.archive.org/web/20200402064158/hllps://arxiv.org/ftp/arxiv/papers/… [cited by applicant]
EP 21779200 Search Report dated Mar. 27, 2024. [cited by applicant]
M. C. (Apr. 24, 2020). Turning up the heat on COVID-19: Heat as a therapeutic intervention. Retrieved Aug. 20, 2020, from https://f1 000research .com/articles/9-292/v1 (Year: 2020). [cited by applicant]
Marcela, M. (May 18, 2020). The Use of Core Warming as a Treatment for Coronavirus Disease 2019 (COVID-19): An Initial Mathematical Model. Retrieved Aug. 20, 2020, from https://jca.emnuvens.com.br/jca/article/view/3382/… [cited by applicant]
Nuvaira. “Minimally Invasive Procedure for COPD Treatment.” Nuvaira, Dec. 26, 2019, web.archive.org/web/20191226085420/www.nuvaira.com/the-procedure/. Accessed Apr. 2, 2021. (Year: 2019). [cited by applicant]
PCT/US2021/015825 International Search Report dated Apr. 29, 2021. [cited by applicant]
PCT/US2023/034606 International Search Report dated Apr. 19, 2024. [cited by applicant]
PCT/US2023/034610 International Search Report dated Mar. 13, 2024. [cited by applicant]
Q&A: Dexamethasone and COVID-19. (Jun. 25, 2020). Retrieved Aug. 20, 2020, from https://www.who.int/news-room/q-a-detail/q-a-dexamethasone-and-covid-19 (Year: 2020). [cited by applicant]
Xu, Z., et al. (Feb. 18, 2020). Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Retrieved Aug. 20, 2020, from https://www.sciencedirect.com/science/article/pii/S221326002030076X?vi… [cited by applicant]
Zurn, R. (May 28, 2020). Ultrasound may prove to be effective, noninvasive treatment for COVID-19. Retrieved Aug. 20, 2020, from https://cse.umn.edu/college/feature-stories/ultrasound-may-prove-be-effective-noninvasive-… [cited by applicant]